Therapeutic antibodies - Delivering the promise?

Advanced Drug Delivery Reviews

Volumn 58, Issue 5-6, 2006, Pages 633-639

  Hale, Geoff ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Therapeutic monoclonal antibodies

Indexed keywords

DISEASES; OPTIMIZATION; PHARMACODYNAMICS;

THERAPEUTIC MONOCLONAL ANTIBODIES;

ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ATLIZUMAB; BASILIXIMAB; CAMPATH 1G; CAMPATH 1M; CPD 870; DACLIZUMAB; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LERDELIMUMAB; MDX 210; MONOCLONAL ANTIBODY; MRA; MYELOTARG; NATALIZUMAB; OKT 3; OSIDEM; PALIVIZUMAB; PEMTUMOMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; EPSTEIN BARR VIRUS; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; INFECTION; KIDNEY GRAFT REJECTION; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; VIRUS INFECTION;

EID: 33747378313     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.03.010     Document Type: Note

References (49)

1. Hericourt J., and Richet C. 'Physiologie Pathologique' - de la serotherapie dans la traitement du cancer. Comptes Rendus Hebd. Seances Acad. Sci. 121 (1895) 567
2. Monoclonal Antibody Therapies. Entering a New Competitive Era (2004), Arrowhead Publishers, Minneapolis
3. Stacy K.M. Therapeutic Mabs: saving lives and making billions. The Scientist 19 (2005) 17-18
4. Kohler G., and Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
5. Currie G.A. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br. J. Cancer 26 (1972) 141-153
6. Milstein C. With the benefit of hindsight. Immunol. Today 21 (2000) 359-364 (Note: this celebratory issue contains several other reviews of historical interest)
7. Miller R.A., Maloney D.G., Warnke R., and Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306 (1982) 517-522
8. Haagen I.-A., Geerars A.J.G., Clark M.R., and van de Winkel J.G.J. Interaction of human monocyte Fc gamma receptors with rat IgG2b: a new indicator for the Fc gamma RIIA (R-H131) polymorphism. J. Immunol. 154 (1995) 1852-1860
9. Clark M., Cobbold S., Hale G., and Waldmann H. Advantages of rat monoclonal antibodies. Immunol. Today 4 (1983) 100-101
10. Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A.J., and Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 (1983) 873-882
11. Hale G., Swirsky D.M., Hayhoe F.G.J., and Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol. Biol. Med. 1 (1983) 321-334
12. Dyer M.J.S., Hale G., Hayhoe F.G.J., and Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73 (1989) 1431-1439
13. Neuberger M.S., Williams G.T., and Fox R.O. Recombinant antibodies possessing novel effector functions. Nature 312 (1984) 604-608
14. Bruggemann M., Williams G.T., Bindon C.I., Clark M.R., Jefferis R., Waldmann H., and Neuberger M. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166 (1987) 1351-1361
15. van de Winkel J.G., and Capel P.J. Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 14 (1993) 215-221
16. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
17. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. Absence of fucose but not the presence of galactose of bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
18. Isaacs J., Wing M.G., Greenwood J., Hazleman B., Hale G., and Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106 (1996) 427-433
19. Riechmann L., Clark M.R., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
20. Cheetham G.M.T., Hale G., Waldmann H., and Bloomer A. Crystal structure of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol. 284 (1998) 85-99
21. Hale G., Dyer M.J.S., Clark M.R., Phillips J.M., Marcus R., Riechmann L., Winter G., and Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2 (1988) 1394-1399
22. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N. Engl. J. Med. 313 (1985) 337-342
23. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330 (1994) 956-961
24. European Commission. Commission Directive 2001/208/EC of the 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off. J. Eur. Union L. 121 1.5 (2001) 34
25. Kirschenbaum L., Astiz M., and Rackow E.C. Antibodies to TNF-alpha: too little, too late?. Crit. Care Med. 26 (1998) 1625-1626
26. Hale G., and Waldmann H. From laboratory to clinic: the story of CAMPATH-1. In: George A.J.T., and Urch C. (Eds). Antibodies in the Clinic: Methods in Molecular Medicine. Diagnostic and Therapeutic Antibodies vol. 40 (2000), Humana Press, NJ 243-266 pub
27. Winter G., and Milstein C. Man-made antibodies. Nature 349 (1991) 293-299
28. Bruggeman M., and Neuberger M. Strategies for expressing human antibody repertoires in transgenic mice. Immunol. Today 17 (1996) 391-397
29. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 23 (2005) 1117-1125
30. Kellermann S.A., and Green L.L. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 13 (2002) 593-597
31. Amin T., and Carter G. Immunogenicity issues with therapeutic proteins. Curr. Drug Discov. 12 (2004) 20-24
32. De Groot A.S., Knopp P.M., and Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122 (2005) 171-194
33. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54 (2002) 531-545
34. Gilliland L.K., Walsh L.A., Frewin M.R., Wise M., Tone M., Hale G., Kioussis D., and Waldmann H. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162 (1999) 3663-3671
35. Clark M.R. Antibody humanization: a case of the 'Emperor's new clothes'?. Immunol. Today 21 (2000) 397-402
36. Reichert J., and Pavlou A. From the analyst's couch: monoclonal antibodies market. Nat. Rev. Drug Discov. 3 (2004) 383-384
37. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
38. Brett S., Baxter G., Cooper H., Johnston J.M., Tite J., and Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 88 (1996) 13-19
39. Cox A.L., Thompson S.A., Jones J.L., Robertson V.H., Hale G., Waldmann H., Compston D.A., and Coles A. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35 (2005) 3332-3342
40. Keating M.J., Flinn I., Jain V., Binet J.-L., Hillmen P., Byrd J., Albitar M., Brettman L., Santabarbara P., Wacker B., and Rai K.R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
41. Lundin J., Kimby E., Bjorkholm M., Broliden P.-A., Celsing F., Hjalmar V., Mollgard L., Rebello P., Hale G., Waldmann H., Mellstedt H., and Osterborg A. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
42. Christiansen J., and Rajasekaran A.K. Biological impediments to monoclonal antibody based cancer immunotherapy. Mol. Cancer Ther. 3 (2004) 1493-1501
43. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh K., Marks J.D., and Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
44. Graff C.P., and Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63 (2003) 1288-1296
45. Azemar M., Djahansouzi S., Jager E., Solbach C., Schmidt M., Maurer A.B., Mross K., Unger C., von Minckwitz G., Dall P., Groner B., and Wels W.S. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to Erb2/HER2. Breast Cancer Res. Treat. 82 (2003) 155-164
46. Folli S., Pellegrin A., Chalandon Y., Yao X., Buchegger F., Lienard D., Lejeune F., and Mach J.P. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int. J. Cancer 53 (1993) 829-836
47. Page M.J., and Sydenham M.A. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (NY) 9 (1991) 64-68
48. Lifely M.R., Hale C., Boyce S., Keen M.J., and Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5 (1995) 813-822
49. Dyer M.J.S., Moser S., Brunker P., Bird P., Almond N., Puentener U., Wheat L.M.W., Bolam E., Berrie E., Grau R., Buckby E., Kennedy B., Stebbings R., Hale G., and Umana P. Enhanced potency of glycoengineered anti-CD52 monoclonal antibodies (MAbs). Blood 106 (2005) (Abstract 2958)